Safety and Efficacy of Iloprost and Eptifibatide Co-administration Compared to Standard Therapy in Patients With Septic Shock - a Randomized, Controlled, Double-blind Investigator-initiated Trial
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
Price : $35 *
At a glance
- Drugs Eptifibatide (Primary) ; Iloprost (Primary)
- Indications Sepsis; Septic shock
- Focus Biomarker; Therapeutic Use
- Acronyms CO-ILEPSS
- 31 Aug 2018 Biomarkers information updated
- 21 Apr 2017 Status changed from recruiting to completed.
- 26 Aug 2016 This trial was completed in Denmark (end date: 11 Aug 2016).